New Delhi, August 13, 2025 — In a major development for diabetes and obesity care in India, Eli Lilly and Company (India) Pvt. Ltd. has officially launched Mounjaro® KwikPen® (tirzepatide) across the country. Approved by the Central Drugs Standard Control Organisation (CDSCO), this once-weekly, prescription-based injection is now available in all dose strengths at registered pharmacies nationwide.
Personalized, Once-Weekly Treatment for Type 2 Diabetes and Obesity
Mounjaro® KwikPen® is a multi-dose, single-patient-use prefilled pen that allows for personalized treatment, administered under medical supervision. The pen contains four doses, taken once a week, and is designed to improve treatment adherence through its convenience and ease of use.
This innovative medication is indicated as an adjunct to diet and exercise for:
- Managing Type 2 Diabetes
- Chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity
Unique Mechanism: Dual GIP and GLP-1 Receptor Agonist
Mounjaro® (tirzepatide) is the first and only dual agonist that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. These incretin hormones help regulate blood sugar levels, enhance insulin secretion, improve insulin sensitivity, reduce glucagon levels, and delay gastric emptying. Mounjaro® has also shown benefits in appetite regulation, weight loss, and fat reduction.
“The launch of Mounjaro® KwikPen® marks a step forward in the care of type 2 diabetes and obesity, offering a more convenient approach to medication administration,” said Winselow Tucker, President and General Manager, Lilly India. “We believe this innovation will support healthcare professionals in delivering more personalized and effective treatment plans.”
Mounjaro® KwikPen® Price and Availability in India
The Mounjaro® KwikPen® is available in six dose strengths:
| Dose Strength | Maximum Retail Price (Per Month) |
|---|---|
| 2.5 mg | ₹14,000 |
| 5 mg | ₹17,500 |
| 7.5 mg | ₹22,000 |
| 10 mg | ₹22,000 |
| 12.5 mg | ₹27,500 |
| 15 mg | ₹27,500 |
Mounjaro® is available only by valid prescription and must be used under the supervision of a qualified healthcare professional. It is not approved for cosmetic weight loss and should be used strictly for medically indicated conditions.
About Lilly
Eli Lilly is a global leader in pharmaceutical innovation, dedicated to turning science into life-changing medicines. With a legacy of nearly 150 years, Lilly is at the forefront of tackling some of the world’s most challenging diseases—including diabetes, obesity, cancer, and Alzheimer’s.
